Coverage
-
March 22, 2018
KaloBios Pharmaceuticals Inc. shareholders asked a California federal judge on Wednesday to approve a $1.5 million deal to resolve claims against former KaloBios CEO Martin Shkreli, marking an end to a securities class action over Shkreli's legal woes.
2 other articles on this case.
View all »